PRESENTATION ON BRAND INDIA PROMOTION

Slides:



Advertisements
Similar presentations
المنظمون السيد / رولف كيرست Mr. Rolf Gerhard Kirst.
Advertisements

CIPLA LTD Analyst Report By Siddharth Ghaisas. WHO IS CIPLA & WHAT DO THEY DO? WHO WHO - The Chemical, Industrial & Pharmaceutical Laboratories; - Founded.
1 Growth of Micro, Small & Medium Enterprises in India.
Pharmaceuticals Limited India – CIS International Pharma Conference 3-5 th March 2006, Mumbai Prashant Nagre Vice President – API Division.
Dr. Sarfraz Bashir, Senior Vice President, Sailkot Chamber of Commerece.
ABOUT US Headquartered in Pune, India, Messung Global Connect is a global advisory & implementation firm assisting global companies to foray into the.
APIs – global business developments Gian Mario Baccalini EFCG Board Member, Chairman of EFCG Pharma Business Committee President, B&P Development Srl,
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
Ensuring Employment and Job Opportunities.  Strengthening economy  Uplifting the living standard of all citizens with decent work opportunities  Development.
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment DAVID HARDING SEOUL JUNE 28-29, 2007.
Eli Lilly and company Matt Spahlinger ACG
SADC Elements of the Regional Action Plan. IMPROVING INDUSTRIAL PERFORMANCE AND PROMOTING EMPLOYMENT.
Development of Local Suppliers for International Businesses Peter Bracher – Managing Director NSF-CMi Asia Pacific February 2011 Overcoming the Challenges.
KPGM-TiE Report.  Availability of finance. unavailability of easy and sufficient finances.  Policy framework from Government. Bureaucracy, Corruption,
INDIA’S INFRASTRUCTURE – Issues and Prospects PRESENTATION BY SS Kohli Chairman & Managing Director INDIA INFRASTRUCTURE FINANCE COMPANY LTD NEW DELHI.
Achieving Long-term Competitive Advantage Regional Economics (310) February 24, 2006 Lorna H. Wallace, Research Fellow.
How to Access a Promising Market? Challenges from the Viewpoint of an Entrepreneur Interested to Access the Indian Market Norbert Gerbsch, PhD Head of.
( An IACBE Accredited Institution ) Industry Analytics Post Graduate Programme (2010 – 12) 3rd Term Alliance Business School Bangalore.
“Make in India Mittelstand” 10 th September 2015, Berlin, Germany.
Governmental initiatives to support Danish companies - Victor Kjaer, Deputy Director General Danish Commerce and Companies Agency.
WIPRO : A STRATEGIC PERSPECTIVE
Global Recognition of the Indian Biotech Sector - The Road Ahead Sept 26,2003 Hyderabad.
PRESENTATION ON BRAND INDIA PROMOTION By Ashutosh Gupta COA Member -Pharmexcil Executive Director -Medicamen Biotech Ltd.
5-1 National Foreign Trade Policy. 5-2 Study Topics  Evolution.  Uniqueness.  Past and the Present.  Achievements.  The power and Limitations. 
“The Quality Infrastructure in Lebanon” Export Norms, Quality Control and Competitiveness FUTURE PROGRAMME Prepared By Ali Berro Director of Quality Programme.
16-17 November 2005 COSCAP – NA Project Steering Group Guangzhou, China 1 Co-operating with the European Aviation safety Agency.
GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.
WORKSHOP ON THE ESTABLISHMENT OF A NATIONAL COMPETITIVENESS AND PRODUCTIVITY COUNCIL FOR SAINT LUCIA Presentation by Laura del Castillo Saviñón, Technical.
Productivity Leadership Program Productivity Growth in the Passenger Transport Industry through Best Practice An initiative of the Australian Chamber of.
INFORMATION AND COMMUNICATION TECHNOLOGY (ICT) POLICY 2014 DEPARTMENT OF INFORMATION TECHNOLOGY GOVERNMENT OF ODISHA.
INCENTIVES AND SCHEMES ASSOCIATED WITH MSMEs. Aims and objectives "Imparting greater vitality and growth impetus to the Micro, Small and Medium Enterprises.
iHEA 9th World Congress Sydney, July 8, 2013
Indian API manufacturers are fit for outsourcing Pharma products
Plastics Machinery Manufacturers Association of India (PMMAI)
OVER 20 YEARS OF EXPERIENCE IN CHEMICAL AND PHARMA INDUSTRY
How we can help you export… Liz Blackford International Trade Adviser
SWOT analysis.
Globalization Unit 5.
WELCOME TO
SWOT ANALYSIS.
Task Force Group For SMIC
Bridging the Gap Increasing Employability
BASICS IN PHARMA.
SMART WAYS TO SETUP ELECTRONICS MFG. IN INDIA.
chambers of commerce do business
Co-operating with the European Aviation safety Agency
SWOT analysis.
China International SME Fair
Michael Porter’s Five Forces Model.
SUBMISSION BY BUSA TO THE PORTFOLIO COMMITTEE ON TRADE AND INDUSTRY REGARDING THE SPECIAL ECONOMIC ZONES BILL 21 MAY 2013 Presenters Ms Nomaxabiso Majokweni.
DEVELOPMENT & IMPLEMENTATION OF A NATIONAL STRATEGY ON CSR
Knowledge Objectives Understand the 4 strategies for foreign expansion
a dynamic industry in a changing world
a dynamic industry in a changing world
Importance of RPA (Robotic Process Automation) in software Testing.
السيد / رولف كيرست Mr. Rolf Gerhard Kirst المنظمون.
Internal Market, Industry, Entrepreneurship and SMEs Directorate General The path towards KETs Neuromorphic computing Workshop Brussels,
Your Global Business Partner!
An Industry Perspective Nicole Denjoy COCIR Secretary General
Suggested Actions for PAN IIT Members
AFIRM History & Industry Landscape for Restricted Substances
HPH Strategy Seminar Beijing, China 7 september 2013 Andrea Limbourg
Trade perspectives in the wine sector
GMP Inspection Process
Automating Profitable Growth™
 Business Feasibility Study Report  Business Model  Project Report  Business Plan  Detailed Project Report Available Reports on this Title –
FUNCTIONING OF AIFS.
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Prof. Kiran Kalia, Director NIPER Ahmedabad
Our Business Philosophy
Presentation transcript:

PRESENTATION ON BRAND INDIA PROMOTION By Ashutosh Gupta COA Member -Pharmexcil Executive Director -Medicamen Biotech Ltd. Email : guptaashutosh@medicamen.com

INTRODUCTION TO SME’S Gross Capital Below 5 Crores. 2. Top Management comprises of 2-3 individuals in most cases. 3.Limited resources. 4.Lack of protection and minimal chances of Bailout. 5.Good source for employment. 6.Lack of automation. 7.Generic Sales / Lack of profitability.

IMPORTANCE OF BRAND INDIA 1.Goes a long way to help SME’S for better exports. 2. Better acceptability of Products & Companies. 3. Better Margins. 4. Better Brand Positioning w.r.t. CHINA. 5.More investments and JV’S. 6.Big opportunity awaiting in 2012 in terms of patents expiring.

BRAND INDIA PROMOTION Special programes to upgrade the industry image abroad as well as inside the country. Pharmacopeal leverage. India’s own Pharma expo in India as well as abroad. Cooperative agreements with FDA’s. Provision of easy finance. Incentive to SME’s for entry into regulated markets. Task should be shared with indians abroad. Need for comprehensive package for the industry.

SPECIAL PROGRAMMES TO UPGRADE THE INDUSTRY IMAGE Trust building of our Government towards our Industry. Road shows abroad. Specific Ministerial delegations. Special diplomatic task force. Designated technical official in important markets in embassies.

2. PHARMACOPEAL LEVERAGE IP is today at par with BP. COPP’s Brand image of Pharmacopia. Leap jump ahead of china. Cost effectiveness. Better Documentation. Better Product Range.

3. INDIA’S OWN PHARMA EXPO Show of strength. We will come at par with other industries. We reach all parts of the world. Better exposure. International Participations.

4. COOPERATIVE AGREEMENTS with FDA’s Better Brand image. Time saving. Cost effective Makes way for FDI’S and JV’S. Pharmacopeal leverage. Increase in exports.

5 PROVISION OF EASY FINANCE SME’S always struggle due to lack of finance. If finance is available more exports can be attained. Easy upgradation towards CGMP/GLP. Concentrated effort on exports. Brand building of products. Better image of Indian industry.

6. INCENTIVES TO SME’S FOR ENTRY INTO REGULATED MARKETS Huge finance required. Bioequivalence Validations. CTD Dossiers. Trained regualatory staff. Huge gestation period. Scope of profitability. Better number in US and EUROPE. Jump in exports. Better brand image. Long lasting effects.

7.TASK SHOULD BE SHARED WITH INDIANS ABROAD Enrolment as associate members. Most of Indians are well established . They will feel more attatched. Broad vision from the markets perspective. First hand information. Provides vast scope for improvement. More Effective Buyer seller meet in India and abroad. Better representation in terms of brand India. We meet good buyers resulting in growth of exports.

8. COMPREHENSIVE PACKAGE NEED International conditions are very volatile. Regulatory authorities becoming more stricter day by day. More Documentations coming into view. More infrastructural requirements. Global Opportunities awaiting us. India gaining image of Best source for low cost good quality generics.

CHALLENGES TODAY Huge Investments- Bioequivalence studies, ANDA and DMF, Validations, stability studies etc Dying API industry. COPP’s ( Certificate of pharmaceutical product ) Pollution norms in API industry Yearly updations. Implementation of GLP Lack of Automation Presence in regulated markets dominated by big pharma Lack of Brand development. Non availablity of easy bank finance. Lack of trained and specialised manpower Lack of confidence of government in Pharma SME’s

SUGGESTIONS Reimbursement of bioequivalence cost atleast 50%. Subsidised API/ ingredient units preferably PSU’s Agreements with FDAs internationally to promote IP Relaxation of pollution norms for the API industry Special Incentive / subsidy for the industry on lines of tuf scheme to take care of yearly Updations GLP upgradation subsidy shall be provided to the industry Automation subsidy shall be provided to compete internationally. Incentive to enter regulated markets Marketing coops abroad should be promoted for brand development. Banking Suggestions ( meeting with secy commerce on 13th) More research centres like NIPER for trained manpower availaibility Provision of a technical person in embassies

OTHER SUGGESTION Development of clusters instead of SEZs Plant approval cost reimbursement to be included in MAI scheme Better incentive to bulk drugs under focus market scheme Subsidy to units for upgradation from schedule M to CGMP.

LET THE VOICE BEGIN

Thank You!